Product claims may differ from country to country based on regulations and product approvals. Please contact your country representative for further details.

»  Suche


Erweiterte Suche

»  News-Alert

Sie möchten über die neuesten Nachrichten und wichtigsten Termine der B·R·A·H·M·S Aktiengesellschaft Informiert werden? Dann tragen Sie sich einfach in unser kostenloses News-Alert-System ein.

Eintragen / Abmelden


Thermo Fisher Scientific schließt zwei durch das Land Brandenburg geförderte Forschungs- und Entwicklungsvorhaben erfolgreich ab

Im Rahmen einer Projektförderung des Landes Brandenburg, vertreten durch die Zukunftsagentur Brandenburg (ZAB) sowie die Investitionsbank des Landes Brandenburg (ILB), erhielt Thermo Fisher Scientific Fördermittel des Europäischen Fonds für regionale Entwicklung (EFRE). In zwei Forschungs- und Entwicklungsprojekten wurden im Zeitraum von April 2009 bis Dezember 2013 innovative Lösungen für die medizinische Diagnostik erarbeitet.


Study Shows Early Rule-Out of Acute Myocardial Infarction using Troponin together with Copeptin is Safe

“Biomarkers in Cardiology 8” study published in European Heart Journal HENNIGSDORF, Germany – (June 17, 2014) – A study conducted by clinicians in leading German, Swiss and Austrian hospitals demonstrates that low-to-intermediate risk patients with suspected Acute Coronary Syndrome (ACS) can safely be discharged earlier from the Emergency Department (ED) using cardiac Troponin together with Copeptin. The study suggests that, by implementing the new process, clinics can better manage overcrowded EDs and increase patient well-being.


diaDexus, Inc. Announces Exclusive U.S. Licensing Deal with Thermo Fisher Scientific to Advance Risk Prediction in Heart Failure

-- Company expands cardiovascular pipeline and aims to address large unmet need for prognosis and risk stratification in patients with heart failure --

SOUTH SAN FRANCISCO, Calif.- (March 05, 2014) - diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced an exclusive licensing and supply agreement with Thermo Fisher Scientific Inc., the world leader in serving science with $17 billion in revenues, that will provide diaDexus with the ability to develop and commercialize three independent biomarkers (MR-proADM (midregional pro adrenomedullin), MR-proANP (midregional pro atrial natriuretic peptide), and CT-proET1 (C-terminal pro endothelin-1)) to aid in risk prediction and prognosis for heart failure.


Thermo Fisher Scientific and bioMérieux Renew Partnership for Improved Detection of Sepsis Using PCT Biomarker Procalcitonin (PCT) Immunoassay is Sustained on VIDAS® Instruments

Marcy l'Etoile, France and Hennigsdorf, Germany (October 2, 2012) – bioMérieux and Thermo Fisher Scientific Inc., the world leader in serving science, today announced they have renewed their non-exclusive, long-term, royalty-bearing agreement for Procalcitonin (PCT) testing. This agreement extends a long-standing relationship between the companies for biomarker testing using Thermo Fisher’s PCT product on bioMérieux’s VIDAS® and mini VIDAS® immunoassay platforms, and now also includes the new-generation VIDAS® products.


Thermo Fisher Scientific Commends Staunton Family & Senate Committee for Continued Efforts in Raising Sepsis Awareness Mr. Ciaran Staunton to Speak about Sepsis at Full Senate Hearing on U.S. Efforts to Reduce Healthcare-Associated Infections

(WALTHAM, MA – September 24, 2013) – Thermo Fisher Scientific applauds the tenacity of the Staunton family, as well as Chairman Tom Harkin and Ranking Member Lamar Alexander, for raising the profile of sepsis education among the public, legislators and other government officials.


Thermo Fisher Scientific and Siemens Renew Partnership for Improved Detection of Sepsis Using B•R•A•H•M•S PCT Biomarker Procalcitonin (PCT) Immunoassay Availability is Continued on ADVIA Centaur® Systems

HENNIGSDORF, Germany – (August 27, 2013) – Hospital laboratories outside the U.S. can benefit from a continued availability of the B•R•A•H•M•S PCT™ assay on ADVIA Centaur® systems, allowing them to diagnose sepsis early and safely.


Thermo Fisher Scientific and Roche Renew Partnership for Improved Detection of Sepsis Using PCT Biomarker Procalcitonin (PCT) Immunoassay is Prolonged on Elecsys® cobas e Instruments

HENNIGSDORF, Germany – (July 30, 2013) – Thermo Fisher Scientific Inc., the world leader in serving science, today announced the renewal of its non-exclusive, long-term, royalty-bearing agreement with Roche for the use of Thermo Fisher’s Procalcitonin (B.R.A.H.M.S PCTTM) technology, currently available as an automated immunoassay on the Roche Elecsys® cobas e platforms in all countries outside the United States. The agreement extends a long-standing relationship between the companies.


Neue Version: Thermo Scientific B·R·A·H·M·S Fast Screen pre I plus V 1.4 für alle KRYPTOR Systeme

Thermo Scientific Biomarkers hat erneut ein Update der CE-zertifizierten Software B·R·A·H·M·S Fast Screen pre I plus auf den Markt gebracht. Die neue Version 1.4 der Software für das Pränatalscreening ist seit Januar 2012 erhältlich und in den Sprachen Deutsch, Englisch und Französisch verfügbar.


Thermo Fisher Scientific PCT Assay for Sepsis Available for Abbott Analyzers More Patients will Benefit from Earlier Detection

WALTHAM, Mass., (January 30, 2012) – Thermo Fisher Scientific, the world leader in serving science, today announced an agreement with global healthcare provider Abbott Laboratories to make its Procalcitonin (PCT) assay available with Abbott’s immunochemistry analyzers.


Prof. Kypros Nicolaides zu Gast bei Thermo Fisher Scientific in Hennigsdorf

Am 1. Dezember 2011 besuchte Prof. Kypros Nicolaides, Direktor des Fetal Medicine Centers und Gründer der Fetal Medicine Foundation (FMF, London), erstmalig den Standort von Thermo Fisher Scientific Biomarkers in Hennigsdorf/bei Berlin.

Seite: 1